Lineage Cell Therapeutics Inc. (LCTX)
NYSE: LCTXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
LCTX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $195.26M
- EPS (TTM)
- -$0.09
- Dividend yield
- None
- Ex-dividend date
- Dec 15, 2003
- 52-week range
- 0.77 – 1.99
- Day range
- 0.77 – 0.8383
- Volume / Avg
- 2.04M / 1.64M
- Beta
- —
- Shares outstanding
- 252.95M
52-week range
LCTX stock today
On Nov 20, LCTX ended the session at $0.7719, shedding $0.0481 (5.87%), versus the S&P 500's 3.70% decline. Shares are 61.2% below their 52-week high of $1.99, set on Feb 26, 2026 and 0.2% above the 52-week low of $0.77, near the bottom of the past year's range. LCTX is down 53.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 55.6%.
Lineage Cell Therapeutics has posted a net loss over the last twelve months (EPS of -$0.09), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Lineage Cell Therapeutics
Company profileLineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; and OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries. It also offers ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of sensorineural hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Brian M. Culley M.A., M.B.A.
- Headquarters
- Carlsbad, CA
- Employees
- 72
- Website
- lineagecell.com
Financial highlights
Full financialsIn fiscal 2025, Lineage Cell Therapeutics generated $14.6 million in revenue, up 53.2% from fiscal 2024, its 2nd consecutive year of revenue growth. Lineage Cell Therapeutics reported a net loss of $63.5 million, compared with a loss of $18.6 million a year earlier. Operating margin was -251.6%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $14.56M | $9.50M | $8.95M | $14.70M | $4.34M |
| Growth | +53.24% | +6.19% | -39.16% | +238.70% | +137.73% |
| Net income | $-63.53M | $-18.61M | $-21.49M | $-26.27M | $-43.02M |
| EPS (diluted) | $-0.28 | $-0.09 | $-0.12 | $-0.15 | $-0.26 |
Analyst forecast
ForecastConsensus (7 analysts)
strong_buy
Avg. price target
$5.50+612.53%
- Strong buy 1
- Buy 5
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-0.13 vs $-0.02
- Surprise
- -550.00%
Dividends
Dividend history- Annual dividend
- $0.00
- Last payment
- $0.0646
- Ex-dividend date
- Dec 15, 2003
LCTX news
All LCTX news- Lineage (LCTX) Q3 2026 Earnings Call TranscriptNasdaqLCTX, WSO.B
- Lineage Cell Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business UpdateBusiness Wire
- Lineage Announces Acquisition of NeuroAirmid Therapeutics and Clinical Stage Program for the Treatment of Huntington’s DiseaseBusiness Wire
- Lineage Cell Therapeutics to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026Business Wire
Lineage Cell Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CABACabaletta Bio Inc. | 0.9361 | -7.32% | $201.94M | vs LCTX |
| ARTVArtiva Biotherapeutics Inc. | 3.78 | -1.31% | $186.85M | vs LCTX |
| IKTInhibikase Therapeutics Inc. | 1.32 | +1.54% | $185.16M | vs LCTX |
| IPSCCentury Therapeutics Inc. | 1.17 | -11.74% | $211.56M | vs LCTX |
| CGENCompugen Ltd. | 1.84 | -2.13% | $174.29M | vs LCTX |
| ALLOAllogene Therapeutics Inc. | 0.6277 | -5.88% | $217.48M | vs LCTX |
| SCTXScribe Therapeutics Inc. | 12.07 | -8.70% | $228.58M | vs LCTX |
| PALIPalisade Bio Inc. | 0.8399 | -9.24% | $150.74M | vs LCTX |
Indexes, lists and sector
Lineage Cell Therapeutics stock FAQ
What is Lineage Cell Therapeutics's stock price today?
LCTX last traded at $0.7719 as of Nov 20, 4:00 PM EST, down 5.87% on the day. Prices are delayed at least 15 minutes.
Does Lineage Cell Therapeutics pay a dividend?
Yes. Lineage Cell Therapeutics pays $0.00 per share annually. The most recent dividend of $0.0646 had an ex-dividend date of Dec 15, 2003.
Who is Lineage Cell Therapeutics's CEO?
Mr. Brian M. Culley M.A., M.B.A. is the chief executive officer of Lineage Cell Therapeutics Inc., which has about 72 employees.
Has LCTX ever split its stock?
Yes. The most recent LCTX stock split was a 3-for-1 split on Oct 31, 1997.
What is the LCTX 52-week high?
The 52-week high for LCTX is $1.99 and the 52-week low is $0.77. The stock is currently 61.2% below its high.